Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory
Version of Record online: 3 MAY 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 21, Issue 12, pages 1251–1260, December 2012
How to Cite
Dusetzina, S. B., Busch, A. B., Conti, R. M., Donohue, J. M., Caleb Alexander, G. and Huskamp, H. A. (2012), Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidem. Drug Safe., 21: 1251–1260. doi: 10.1002/pds.3272
- Issue online: 6 DEC 2012
- Version of Record online: 3 MAY 2012
- Manuscript Revised: 7 MAR 2012
- Manuscript Accepted: 7 MAR 2012
- Manuscript Received: 1 NOV 2011
- Agency for Healthcare Research and Quality. Grant Number: RO1 HS0189960
Additional supporting information may be found in the online version of this article:
Supplemental Table 1. Timeframes for assessment.
Supplemental Table 2. Programmatic definitions of select covariates.
Supplemental Table 3. Second generation antipsychotic use: multivariate model estimates.
|pds_3272_sm_tables.doc||Word document||236K||Supplementary Material|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.